tm logo
CLICKMER
Live/Pending
PUBLICATION/ISSUE REVIEW COMPLETE

on 10 Apr 2024

Last Applicant/ Owned by

Marie-Curie-Straße 5

Rheinbach

DE

53359

Serial Number

97677631 filed on 15th Nov 2022

Registration Number

N/A

Correspondent Address

LEIGH ANN LINDQUIST SUGHRUE MION, PLLC

2000 Pennsylvania Avenue NW, Suite 9000

Washington, DC 20006

UNITED STATES

Filing Basis

No Filing Basis

Disclaimer

NO DATA

CLICKMER

Scientific research and development for third parties, especially in the fields of diagnostics, pharmaceuticals, chemistry, biology, biochemistry and biotechnology; scientific and technological services, namely, providing medical research information and scientific research information, feasibility studies, testing services and analysis services in the fields of diagnostics, pharmaceuticals, chemiRead More

Classification Information


Class [044]
Medical, Beauty & Agricultural Services


Medical and veterinary services; medical and veterinary diagnostic services, namely, laboratory services for diagnosis of diseases and genetic defects


First Use Date in General

11th 000101

First Use Date in Commerce

11th 000101

Class [042]
Computer & Software Services & Scientific Services


Scientific research and development for third parties, especially in the fields of diagnostics, pharmaceuticals, chemistry, biology, biochemistry and biotechnology; scientific and technological services, namely, providing medical research information and scientific research information, feasibility studies, testing services and analysis services in the fields of diagnostics, pharmaceuticals, chemistry, biology, biochemistry and biotechnology; scientific laboratory and chemical, biological, biochemical, biotechnological and pharmaceutical analytical services


First Use Date in General

11th 000101

First Use Date in Commerce

11th 000101

Class [005]
Pharmaceutical Products


Chemical, biological, biochemical, biotechnological and pharmaceutical products and preparations, namely, DNA/RNA oligonucleotides, antibodies, nucleic acids, proteins, lipids, polysaccharides, enzymes, peptides, microorganisms, cell cultures and cells as well as fragments, fractions and derivatives thereof, for medical, veterinary or pharmaceutical purposes, namely, for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination and immunostimmulation; therapeutic agents for medical, veterinary and pharmaceutical purposes, namely, for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination and immunostimmulation, medicaldiagnostic agents for medical, veterinary and pharmaceutical purposes; preparations for health care, namely, medicinal preparations for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination and immunostimmulation; Medicines for for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination and immunostimmulation, vaccines


First Use Date in General

11th 000101

First Use Date in Commerce

11th 000101

Class [001]
Chemical Products


Chemical preparations, biological preparations and biochemical preparations for industrial and scientific use; Biotechnological preparations, namely, cells, proteins, enzymes, peptides, cultures of microorganisms for industrial and scientific use; Chemical preparations, biological preparations, biochemical preparations and biotechnological preparations, namely, diagnostic preparations other than for medical or veterinary purposes; Chemical additives for use in the manufacture of pharmaceuticals; Chemical, biological, biochemical and biotechnological products and preparations for use in the manufacturing of pharmaceuticals, namely, DNA/RNA oligonucleotides, antibodies, nucleic acids, proteins, lipids, polysaccharides, enzymes, peptides, microorganisms, cell cultures and cells as well as fragments, fractions and derivatives thereof


First Use Date in General

11th 000101

First Use Date in Commerce

11th 000101

Mark Details


Serial Number

No 97677631

Mark Type

No Service Mark

Attorney Docket Number

No S26278

44D Filed

Yes

44D Current

No

44E filed

No

44E Current

Yes

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
24th Apr 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08th Apr 2024APPROVED FOR PUB - PRINCIPAL REGISTER
13th Mar 2024TEAS/EMAIL CORRESPONDENCE ENTERED
13th Mar 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
12th Mar 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
13th Dec 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
13th Dec 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
15th Sep 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
15th Sep 2023NON-FINAL ACTION E-MAILED
15th Sep 2023NON-FINAL ACTION WRITTEN